Latest Triptorelin Stories
Trelstar® one-, three-, and six-month dosing options now available TORONTO and LAUSANNE, Switzerland, September 30, 2014 /PRNewswire/ -- Trelstar(R) (triptorelin
LAUSANNE, Switzerland, January 13, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the
WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E.
NEW YORK, Oct. 27 /PRNewswire/ -- Drugs, known as gonadotropin-releasing hormone (GnRH) agonists, may raise diabetes and heart risk and, as a result, now need new warnings. U.S.
SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGONÂ® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr.